Vipergen Revenue
Biotechnology Research • 
Copenhagen, Capital Region of Denmark, Denmark • 11-20 Employees
Vipergen revenue & valuation
| Annual revenue | $1,112,215 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $3,600,000 |
| Total funding | No funding |
Key Contacts at Vipergen
Leif Kongskov Larsen
Director Biology
Allan Beck Christensen
Director Of Screening Technologies
Company overview
| Headquarters | Gammel Kongevej 23A, Copenhagen, 1610, DK |
| Phone number | +4528851758 |
| Website | |
| NAICS | 541714 |
| Keywords | Drug Discovery, Small Molecules, Dna-Encoded Chemical Libraries, Protein-Protein Interaction Inhibitors, Molecular Glue, Del Screening In Living Cells, Dels In Cells, Membrane Protein Inhibitors |
| Founded | 2005 |
| Employees | 11-20 |
| Socials |
Vipergen Email Formats
Vipergen uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 42.1% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name}@company.com | john.doe@company.com | 42.1% |
{first name}@company.com | john@company.com | 25.3% |
{first name initial}{last name}@company.com | {first name initial}doe@company.com | 14.8% |
{first name}{last name}@company.com | johndoe@company.com | 10.2% |
{last name}@company.com | doe@company.com | 7.6% |
About Vipergen
Vipergen is a world leading provider of small molecule drug discovery services based on DNA-encoded library (DEL) technologies. Vipergen is finding tractable hits/leads for your pharmaceutical relevant targets, using three proprietary 2nd and 3rd generation DEL technologies. Vipergen is offering different business models, including simple Fee-For-Service. Recent News - Copenhagen, Denmark, November 6th, 2020 - Commercial release of the first technology for DEL screening inside a living cell - Vipergen ApS announced today the commercial release of the first technology for screening of DNA-encoded small molecule libraries (DELs) inside a living cell. This proprietary technology will significantly accelerate and improve the drug discovery process. YoctoReactor® – Technology platform for synthesizing DNA-encoded chemical libraries • 100% match between the DNA-code and the synthesized small molecule is ensured by purification steps after each chemical reaction (unique capability) and use of robust chemistries Binder Trap Enrichment® – Technology platform for DEL screening in a homogeneous assay • As a homogeneous assay, BTE delivers high fidelity and a low false positive rate by avoiding surface artifacts and the complexity of matrix binding • Instant specificity – multiplexed screening of target and anti-targets (unique capability) Cellular Binder Trap Enrichment® – Technology platform for DEL screening in a living cell • As an in vivo assay, cBTE delivers lower attrition rate (unique capability) • No need for purified active target protein – cBTE accommodates a broader target space (unique capability)
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Vipergen has 2 employees across 1 departments.
Departments
Number of employees
Funding Data
Vipergen has never raised funding before.
Sweden
El Salvador
United States
United Kingdom
Belgium
CanadaFrequently asked questions
4.8
40,000 users
